Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
TORONTO—-FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors. Mr. Urban is an accomplished business and government […]
Nancy Bush Huber brings over 25 years of executive management roles, primarily as CFO of several publicly traded and private companies- Most recent position was as CFO of consumer packaged goods company for 13 years- […]
VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
